Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Teva
Mallinckrodt
Cipla
Daiichi Sankyo
Moodys
Chubb
Julphar
Queensland Health

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,856,529

« Back to Dashboard

Which drugs does patent 5,856,529 protect, and when does it expire?

Patent 5,856,529 protects HETLIOZ and is included in one NDA.

This patent has twenty-nine patent family members in twenty-four countries.
Summary for Patent: 5,856,529
Title: Benzofuran and dihydrobenzofuran melatonergic agents
Abstract:Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.
Inventor(s): Catt; John D. (Southington, CT), Johnson; Graham (Madison, CT), Keavy; Daniel J. (Killingworth, CT), Mattson; Ronald J. (Meriden, CT), Parker; Michael F. (Middletown, CT), Takaki; Katherine S. (Middletown, CT), Yevich; Joseph P. (Southington, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:08/987,478
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,856,529

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,856,529

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,981,571 Benzodioxa alkylene ethers as melatonergic agents ➤ Sign Up
6,060,506 Benzopyran derivatives as melatonergic agents ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,856,529

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 476758 ➤ Sign Up
Russian Federation 2190609 ➤ Sign Up
Portugal 1027043 ➤ Sign Up
Poland 190499 ➤ Sign Up
Poland 333950 ➤ Sign Up
New Zealand 335910 ➤ Sign Up
Norway 321450 ➤ Sign Up
Norway 992804 ➤ Sign Up
Japan 4290765 ➤ Sign Up
Japan 2001505916 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Healthtrust
Julphar
McKesson
Accenture
Dow
Covington
Queensland Health
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot